Insider Trading Roundup: Cumberland Pharmaceuticals Inc. $CPIX

fbb0fe2897520ce17fcaefe25634b947

Cumberland Pharmaceuticals Inc. (CPIX) insider have most recently took part in a trading activity. On Aug 23, 2017 Bonner Michael, CFO bought 500 shares having total worth of $3,360 at the price of $6.72 per share, following the transaction a total of 15,447 shares owned by Bonner Michael. Before this latest buy, Bonner Michael purchased CPIX at 3 other times during the past twelve months, for a total investment of $12,813 at an average of $6.29 per share.

The stock has experienced a total of 2 insider trades in the past three months. These trades include 1 sell activities and 1 buy trades. Furthermore, over the past 12 months , the stock was traded 8 times by insiders. In 4 of these trades, the insider was a seller while an employee of the company was the buyer in 4 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 1 1 6.41%
12 Month 4 4 56.91%

Shares of Cumberland Pharmaceuticals Inc. (CPIX) traded up 2.56% on Aug 24, 2017, hitting $6.81. 26,787 shares of the company’s stock traded hands. Cumberland Pharmaceuticals Inc. has a 52 week low of $4.27 and a 52 week high of $7.07. The company’s market cap is $79 million.

Cumberland Pharmaceuticals Inc. (CPIX) last announced its earnings results on Aug 8, 2017. The company reported -0.05 earnings per share (EPS) for the quarter. The company had revenue of $9 million for the quarter During the same quarter in the previous year, the company posted 0.04 earnings per share. The company’s revenue for the quarter was up 17% on a year-over-year basis.

2017-08-08 2017-05-15 2017-03-07 2016-11-01 2016-08-02 2016-05-10 2016-03-03 2015-11-03 2015-08-04 2015-03-03
earnings per share -0.05 0.02 -0.05 0.06 0.04 0.02 0.03 0.04 0.09 0.10
Revenue(M) 8.67 9.64 9.08 8.79 7.42 7.74 8.04 7.89 8.91 9.33

Cumberland Pharmaceuticals Inc., was incorporated in Tennessee on January 6, 1999. It is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company’s target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 65 sales representatives and managers as of March 1, 2013. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which they do business. It promotes Acetadote and Caldolor through its dedicated hospital sales team and currently utilize two distinct sales teams to address its primary target markets: a hospital sales force for the acute care market and a field sales force for the gastroenterology market. It competes with the product attributes such as efficacy, safety, ease-of-use and cost-effectiveness.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.